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Abstract 
 
Background: Eosinophilic esophagitis (EoE) is a rapidly emerging, chronic inflammatory, genetically impacted disease of the 
esophagus, defined clinically by symptoms of esophageal dysfunction and, pathologically, by an eosinophil-predominant tissue 
infiltration. However, in four EoE-families, we have identified patients presenting with EoE-typical and corticosteroid-responsive 
symptoms, but without tissue eosinophilia. It was the aim of this study to clinically and immunologically characterize these patients 
with EoE-like disease.  
Methods: Five patients suffering from an EoE-like disease were evaluated with endoscopic, histologic, functional and quantitative 
immunohistologic examinations, and mRNA expression determination.  
Results: The frequency of first generation offspring of EoE-like disease patients affected by EoE or EoE-like disease was 40%. 
Immunofluorescence analysis confirmed an almost complete absence of eosinophils in the esophageal tissues of patients with 
EoE-like disease, but revealed a considerable T cell infiltration, comparable to EoE. In contrast to EoE, eotaxin-3 mRNA and 
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protein were markedly reduced in EoE-like disease (P < 0.05). The mRNA expression levels of three selected EoE genes (eotaxin-
3, MUC4 and CDH26) allowed to discriminate between EoE-like disease, EoE and normal epithelium.  
Conclusions: Patients suffering from “EoE without eosinophilia” do not fulfill formally the diagnostic criteria for EoE. However, their 
clinical manifestation, immunohistology and gene-expression pattern, plus the fact that they bequeath EoE to their offspring, 
suggest a uniform underlying pathogenesis. Conventional EoE, with its prominent eosinophilia, therefore appears to be only one 
phenotype of a broader “inflammatory dysphagia syndrome” spectrum. In this light, the role of the eosinophils, the definition of EoE, 
and its diagnostic criteria must likely be reconsidered. 
 
Eosinophilic esophagitis (EoE) is a recently recognized, rapidly emerging, chronic inflammatory disease of the esophagus, 
characterized clinically by symptoms of esophageal dysfunction and, histopathologically, by an eosinophil-predominant tissue 
infiltration (1). EoE has strong genetic and environmental components, with a risk of EoE for other siblings estimated at 2.4% and a 
sibling recurrence-risk ratio greater than 40 (2). Several genetic variants are associated with EoE (3), but one twin study has 
highlighted the preponderant role of a common environment in EoE susceptibility (2). Consequently, families with more than one 
affected member are frequently observed (4,5). Interestingly, familial and sporadic EoE have identical clinical manifestations, 
endoscopic features, histologic abnormalities, and even similar molecular background (4). 
 We report here on four EoE families with at least one member exhibiting confirmed EoE and at least one member suffering 
from an “EoE-like” disease, clinically resembling EoE with severe dysphagia up to bolus impaction and responding to topical 
corticosteroids, but without detectable esophageal eosinophilia. This observation raises several fundamental questions regarding 
EoE’s pathogenesis, prompting us to investigate the underlying immunopathogenic and molecular mechanisms of this EoE-like 
disease, and to compare findings to conventional EoE patients and healthy individuals.  
 
Materials and methods 
Identification of EoE-families and patients with EoE-like disease  
The Swiss EoE Clinic in Olten, Switzerland, established in the early 1990s, is a national tertiary referral center for suspected or 
confirmed EoE patients. The catchment area includes all of Switzerland (some 8 million inhabitants).  Diagnostic and therapeutic 
procedures correspond to established standards (1). 
 The Swiss EoE Clinic currently attends 417 EoE patients, including 60 with at least one direct family member also having 
confirmed EoE. An additional 52 patients report a family member with clinically suspected, but not yet confirmed, EoE. These 112 
patients originate from 46 families. In four of these families, we have identified five members suffering from severe dysphagia, but 
not fulfilling EoE’s histopathologic criteria.  
 To enhance our understanding of this still-enigmatic disease, we evaluated these five intriguing patients clinically, 
endoscopically, histologically, immunohistologically, functionally (3/5), with gene expression analysis, and allergologically (3/5). We 
then compared findings to patients having active conventional EoE and to esophagus-healthy controls (normal epithelium, NE). The 
local Ethics Committee approved data collection into the Swiss EoE Database. All participants provided written informed consent. 
 
Endoscopy, tissue sampling and histologic analyses  
Upper endoscopies were performed, assessed and recorded in all five patients by board-certified gastroenterologists (AS and PH). 
Patients were sedated with intravenous propofol, starting with a dose of 0.5 mg/kg body weight. A standard video instrument 
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(Pentax EG-2940 K, Asahi Optical Co. Ltd., Tokyo, Japan) was used and all findings were documented. The global appearance of 
endoscopic abnormalities was assessed and, in addition, each sign associated with eosinophilic esophagitis (EoE) was recorded 
using the EREFS (Exudates-Rings-Edema-Furrows-Strictures) classification (6). In acknowledgement of the disease’s patchy 
nature (7-9), at least four biopsy specimens were taken from the upper half and four from the lower half of the esophagus, using 
commercially-available endoscopic biopsy forceps (Boston Scientific Radial Jaw 4; Boston Scientific Corporation, Natick, MA, USA; 
and Olympus FB-11K-1; Olympus Medical Systems Corporation Tokyo, Japan). A standard video instrument (Pentax EG-2940 K, 
Asahi Optical Co. Ltd., Tokyo, Japan) recorded all findings that were then documented.  
All esophageal biopsies were evaluated by an EoE expert pathologist (ChB); in particular, the eosinophils in the most 
densely infiltrated area were counted in five consecutive HPFs (high-power fields) (Zeiss Axiophot, Plan-Neofluar 40, ocular 
magnification 10x, area of microscopic field 0.3072 mm2) and EoE-associated signs, such as spongiosis, papillary elongation and 
basal zone hyperplasia, as well as the amount of subepithelial fibrosis, were determined semi-quantitatively, as previously 
described (10,11).  
 
Immunofluorescence and immunohistochemistry (IHC) 
Immunofluorescence of formalin-fixed, paraffin-embedded (FFPE) biopsies from the five EoE-like patients (EoE-like) (m/f: 1/4; 
mean age: 60.2 yrs), eight conventional EoE patients (EoE) (m/f: 6/2; mean age: 36.1 yrs), and three NE controls (m/f: 1/2; mean 
age: 32.7 yrs) determined the expression of eosinophil peroxidase (EPX), CD3, mast cell tryptase (MCT), chemoattractant 
receptor-homologous molecule (CRTH2), thymic stromal lymphopoietin (TSLP) and lympho-epithelial Kazal-type-related inhibitor 
(LEKTI) (10-12). Primary antibodies used: anti-EPX (Lee Laboratory, Mayo Clinic, AZ); anti-CD3 (DakoCytomation, Glostrup, 
Denmark and Lab Vision/NeoMarker, Thermo Fisher Scientific, Fremont CA); anti-MCT (DakoCytomation); anti-CRTH2 and anti-
TSLP (Santa Cruz Biotechnology Inc., Santa Cruz, CA); and anti-LEKTI (Novus Biologicals, Littleton, CO). A confocal laser 
scanning microscope (LSM 510, Carl Zeiss, Jena, Germany) analyzed the 20 fields of highest activity (1000x magnification, total 
area=0.34 mm2), except for LEKTI analysis (450x magnification, total area=0.265 mm2). Infiltrating T cell CRTH2 expression was 
obtained in a double staining of CRTH2 and CD3 (11). Extracellular EPX deposits and epithelial cell TSLP and LEKTI expression 
were evaluated semi-quantitatively using scores described previously (10-12).  
For epithelial eotaxin-3 and TNF-α expression, samples were analyzed by indirect IHC, as previously described (13). Anti-
TNF-α (Novus Biologicals) and anti-eotaxin-3 (R&D Systems, Minneapolis MN) served as primary antibodies. Evaluation was 
performed using a light microscope (Fluorescence Microscope Observer.Z1, Carl Zeiss, Germany) at 630x magnification (total 
area=0.44 mm2) and we analyzed the 20 fields of highest activity. TNF- positive cells were counted and semi-quantitative scores 
determined staining intensity of eotaxin-3 expression (10-12).  
 
mRNA expression of EoE genes 
Genome-wide association (GWA) analyses show that EoE has a distinct mRNA expression pattern, a so-called EoE transcriptome, 
consisting of approximately 500 genes (14). The EoE diagnostic panel (EDP), a representative set of 94 EoE genes with an 
approximate 96% sensitivity and 98% specificity, discriminates among EoE, gastroesophageal reflux disease (GERD) and NE (15). 
Complementing the established clinical and histologic approach, EoE can also be diagnosed at a molecular level by mRNA 
expression in FFPE biopsies (15,16). TaqMan Low Density Arrays (TLDA) from three EoE-like patients (m/f: 1/2, one of them at 2 
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different examinations, mean age: 57.33 yrs); four conventional EoE patients (m/f: 1/3 mean age: 30.25 yrs); and four NE 
individuals (m/f: 1/3, mean age: 42.75 yrs) analyzed a gene set of 94 transcripts, including genes dysregulated in treated and 
untreated EoE as well as control genes. Briefly, Aegis Sciences Corp (Nashville, TN) performed RNA extraction and TLDA PCR 
(polymerase chain reaction) on 4-5 10-µm FFPE biopsies, as described previously (15,17). Genes were analyzed only if the 
expression level was detectable in at least 4/13 biopsies. Raw data were normalized to glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) expression and the difference in gene expression calculated by the Delta-Delta-Ct method. 
 
Radiological and functional examinations  
In order to exclude morphological abnormalities, motility disorders and gastro-esophageal reflux, we performed a barium swallow, 
high resolution esophageal manometry with Manoscan 360 (Given Imaging Limited, Yoqneam, Israel) and 24-hour impedance pH-
Monitoring with ZepHr® (Sandhill Scientific, Highlands Ranch, CO, USA). 
 
Allergological work-up 
After a comprehensive medical history, three patients with EoE-like disease underwent a skin prick test with a panel of 
environmental and food allergens applied on the forearm and read after 20 min. Histamine served as a positive, and sodium 
chloride as a negative, control (ALK Abello AG, Volketswil and Allergopharma AG, Therwil, Switzerland). The patch test provided 
an additional allergic challenge with application of aeroallergens (house dust mites, pollens, animal danders; Stallergenes AG, 
Dietikon, Switzerland), and native food (cow’s milk, chicken eggs, rye and wheat flour, soy, carrots) on the back for 48 hours using 
Finn chambers, and evaluated at days 3 and 4. Peripheral blood levels of total immunoglobulin (Ig) E (normal value <100 kU/l), 
specific IgE to an environmental allergen mix (Sx1, normal value <0.35 kU/l) and allergen components (microarray with 112 
allergens; ImmunoCAP ISAC, Thermo Fisher Scientific, Uppsala, Sweden) were measured, according to the manufacturer’s 
instructions.  
 
Statistical analysis 
Data analysis was performed by HUS using the unpaired t test, and significance set at 0.05. Semi-quantitative, immunohistometric 
data were graded accordingly: 0 (absent, 0); + (mild, 1); ++ (moderate, 2); +++ (strong, 3); ++++ (very strong, 4). Biopsies from 
EoE-like patients were obtained and analyzed at different times during follow-up. Data represent means ± standard deviation of all 
available biopsies. For mRNA quantification, only data points above the detection limit are presented. Individual biopsies were 
considered as independent points; the median is shown. A non-parametric Kruskal-Wallis test was performed and multiple 
comparisons were corrected with Dunn’s Multiple Comparison test.  
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Results 
Pedigrees emphasize a strong inheritance 
All 57 individuals from these four EoE-families were Caucasian. Four females and one male were identified as having the atypical, 
so-called “EoE-like” disease, but both male and female first generation offspring are afflicted with conventional EoE (Fig. 1). In 
family A, 1/2 (A.II.1) 1st generation children had confirmed, conventional EoE. In family B, 2/5 (B.II.7 and B.II.8) 1st generation had 
confirmed, conventional EoE, 1/5 suspected but unconfirmed (refused endoscopy) EoE-type pathology (B.II.5), and 1/5 with one 
EoE-like disease, B.II.2, mother to EoE patient, B.III.2, 1/2 children from the 2nd generation. In family C, 1/4 (C.II.7) 1st generation 
offspring has confirmed, conventional EoE as did another 1/10 (C.III.3) in the 2nd generation. Interestingly, neither parent of C.III.3 
was affected with EoE or EoE-like disease. In family D, 1/4 (D.II.5) 1st generation offspring has conventional EoE and 1/4 (D.II.4) 
with EoE-like disease, and 1/4 (D.II.7) has suspected, but unconfirmed (refused endoscopy) EoE-type pathology, but 0/9 (as of this 
writing) in the subsequent 2nd generation. Therefore, 33% of the 1st generation offspring of EoE-like disease patients were affected 
by conventional EoE, and even 40% by EoE or EoE-like disease (only offspring of EoE-like disease patients are included in this 
calculation, Fig. 1). Taken together, these data suggest a strong and common inheritance of EoE and of EoE-like disease. 
  
The clinical manifestation of EoE-like disease is similar to conventional EoE 
As in conventional EoE, the leading symptom in all EoE-like syndrome patients was dysphagia for solids with food impactions 
(1,5,18), in one patient requiring even endoscopic food removal. Chest pain was present in 2/5 patients. Both dysphagia and chest 
pain persisted despite high-dose PPI treatment. In contrast, all these disturbances responded rapidly, in 4/5 patients even 
completely, to treatment with swallowed topical corticosteroids. Of note, symptoms relapsed in all patients shortly after medication 
cessation. Summarizing, the clinical manifestation of EoE-like disease is similar to conventional EoE (1,5,9,18). Table 1 
summarizes demographic, clinical and disease-specific characteristics of the five EoE-like disease patients. 
 
Lack of evident endoscopic abnormalities in EoE-like patients 
Except for discreet mucosal irregularities, such as fine nodules and subtle rings, endoscopies in all EoE-like patients were 
unremarkable. Established EoE-associated signs (6), e.g., edema, furrows and white exudates, were not detectable, even on 
repeated examinations (Fig. 2A-C and Table 1). 
 
Exclusion of distinct functional abnormalities and GERD in patients with EoE-like disease  
The barium swallow performed in 4/5 patients was inconspicuous, showing a normal sized esophagus with a timely passage of the 
contrast agent without any narrowing or signs of dysmotility. High-resolution manometry and 24-hour impedance pH monitoring 
performed in 3/5 patients revealed neither pathologic gastro-esophageal reflux nor a specific dysmotility pattern.  
 
Histological re-examination revealed no relevant tissue eosinophilia 
Re-evaluation of all HE-stained esophageal biopsies from EoE-like patients revealed few lymphocytes and non-specific signs of 
chronic inflammation, e.g., basal zone hyperplasia and papillary elongation. Notably, no eosinophils were detected, except for two 
single eosinophils in 1/40 HPFs found in 1/8 biopsies from patient 5 (Fig. 2D-F and Table 1). 
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Quantitative immunohistological analyses confirm lack of eosinophilia, but reveal a strong T cell and moderate mast cell 
infiltration  
In contrast to conventional histologic examination with HE staining which showed no tissue eosinophilia in EoE-like patients, double 
staining with EPX (eosinophil peroxidase) antibody and propidium iodide (PI) revealed a few eosinophils (Fig. 3A and Fig. S1). Per 
definitionem (1,18), we found a pronounced epithelial eosinophilic infiltration in patients with conventional EoE, but no eosinophils 
in the esophageal epithelium of healthy controls (NE) (Fig. 3A). Notably, we discerned no evidence of already degranulated and 
destroyed eosinophils (no extracellular EPX deposition) in EoE-like disease patients (Fig. 3A). Moreover, the almost complete 
absence of both tissue eosinophils and extracellular EPX deposits were constant findings throughout the follow-up (up to 6 years) 
(Fig. S1).  
Compared to NE, most EoE-like disease patients had, as in conventional EoE (1,5,18), a significant increase in esophageal 
T cells that remained stable throughout follow-up (Fig. 3B and Fig. S1). Of note, the T cells were largely CRTH2-negative (Fig. 3B) 
and found primarily in a peripapillary location (Fig. 3B).  
Tryptase staining revealed more mast cells in samples from EoE-like disease patients compared to NE, but still markedly 
fewer than in conventional EoE (Fig. 3C); this, too, remained relatively stable throughout follow-up (Fig. S1). 
 
Slightly increased epithelial cytokine expression, but no barrier defect in EoE-like disease 
Considering the lack of eosinophilic esophageal infiltration in EoE-like disease, measurements of chemokine and cytokine 
expression involved in eosinophilic recruitment (1,18) showed interesting results. Compared with conventional EoE, epithelial 
eotaxin-3 expression levels were significantly lower in EoE-like disease patients, being even within the healthy range (Fig. 4A). 
Increased expression of the cytokines, TSLP and TNF-α, was observed in some EoE-like disease patients, though conventional 
EoE patients tended to exhibit higher levels (Fig. 4B and 4C). Note that many healthy controls also showed TNF-α positive 
epithelial cells (Fig. 4C). 
LEKTI, a protease inhibitor responsible for epithelial homeostasis, is reportedly reduced in active EoE, implying an epithelial 
barrier defect (12). EoE-like disease patients exhibited significantly higher LEKTI expression by epithelial cells as compared with 
conventional EoE, and no difference was observed relative to normal esophagus (Fig. 4D). 
 
EoE-like disease and conventional EoE share similar gene expression abnormalities, but mRNA expression levels of three 
genes enable a discrimination between EoE-like disease, EoE and NE 
Assessment of mRNA expression levels of 94 transcripts identified previously as being dysregulated in EoE (EDP) provided insight 
into the molecular pathogenesis of EoE-like disease (15). Using a low density array, quantitative mRNA level determination in 
FFPE tissue sections showed a significant up-regulation of eotaxin-3 mRNA in conventional EoE, but was below the detection limit 
in EoE-like disease and NE (Fig. 5). We identified significant changes in the mRNA expression of several genes known to be 
dysregulated in IL-13-stimulated esophageal epithelial cells (15,16). In EoE-like disease, CDH26, KCNJ2, UPKB were strongly up-
regulated, though not quite to conventional EoE levels, while MUC4 was comparable in the two pathologies (Fig. 5). DSG1 was 
significantly down-regulated in conventional EoE compared with controls (Fig. 5). Generally, in EoE-like disease, gene 
dysregulation levels were either comparable to conventional EoE or between conventional EoE and NE. Recapitulating, mRNA 
expression of MUC4 and CDH26 genes differentiated between EoE-like disease and healthy controls, whereas eotaxin-3 mRNA 
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expression differed significantly between EoE-like disease and conventional EoE. These data suggest that EoE-like disease is a 
phenotypical variant of EoE, with some uniform underlying molecular pathogenesis.  
 
Discussion 
EoE is characterized clinically by symptoms of esophageal dysfunction and histopathologically by an eosinophil-predominant 
esophageal infiltration (1,9,18). We present here a series of patients, all with at least one family member having conventional EoE, 
suffering from PPI-refractory symptoms of severe esophageal dysfunction and thereby fulfilling formally the clinical EoE diagnostic 
criteria. Intriguingly, histological examination of serial biopsies failed to detect esophageal eosinophilia in these patients who, 
therefore, do not fulfill EoE’s histopathologic requirement. Provocatively, one could designate the EoE-like disease as “EoE without 
eosinophilia”. This so-far unrecognized disease has the potential to provide new insights into EoE’s pathogenesis.  
 Similarities between conventional EoE and EoE-like disease include a common PPI-refractory cardinal symptom (dysphagia 
for solids, up to food impaction requiring endoscopic bolus removal), and rapid symptom improvement after swallowed topical 
corticosteroids which relapses after medication cessation (1,5,18).  
Mechanisms leading to EoE’s esophageal dysfunction are poorly understood (1), though cellular components, in particular 
eosinophils and mast cells with their preformed substance release, are suspect (1,18). Our novel results show clearly that EoE 
dysphagia is not necessarily linked to eosinophils or an eosinophil-related mediator in esophageal tissue, possibly elucidating the 
disappointing outcomes of eosinophil-targeted treatments, such as the anti-IL-5 antibodies, mepolizumab and reslizumab, where 
esophageal dysfunction persisted despite achieving a marked (>50%) reduction in tissue eosinophilia (10,19,20). Other clinical 
trials likewise report a poor correlation between symptoms and the density of tissue eosinophilia (21,22), suggesting a likely non-
essential role of eosinophils in symptom provocation.  
In contrast to their striking difficulty in swallowing, EoE-like disease patients had only minimal, or even no, endoscopic 
abnormalities. Almost all established inflammatory signs of EoE, such as white exudates, furrows and edema (6), were absent, 
suggesting two conclusions: Firstly, EoE’s endoscopic pattern probably relies on the presence of eosinophils; and secondly, based 
on its inconspicuous endoscopy, EoE-like disease risks being undiagnosed or misinterpreted as functional dysphagia (23). 
 On average, 40% of the first generation offspring of EoE-like disease patients exhibited either confirmed, conventional EoE 
or EoE-like disease, suggesting that these two phenotypes have a common genetic and pathogenic background. In sporadic EoE, 
2/3 of patients are male (1,5,18). One hallmark of multifactorial inheritance is that, when affected, the gender the least likely to have 
the disease is the most likely to produce affected offspring (14). Affected females are thus the most likely gender to produce 
affected offspring. Indeed, all female EoE-like disease patients had children with EoE, whereas neither child of the male patient was 
affected by the disease.  
One could argue that EoE-like disease patients have a hidden eosinophilia due to: the patchy nature of the inflammation 
(7,8); eosinophils located in deeper, sub-epithelial wall layers; a previous degranulation; or to progression from inflammatory to 
fibrotic disease (24,25). In all patients, aggressive, structured epithelial and lamina propria tissue sampling from all esophageal 
segments revealed no relevant eosinophilic infiltration, either with HE or IHC EPX staining. The lack of fibrosis, endoscopically and 
histologically, provides a strong argument against non-inflammatory end-stage EoE. Ergo, the risk of missing a hidden eosinophilia 
in these patients is small and they likely suffer from a non-eosinophilic phenotype of immune-mediated esophagitis. 
 As blood eosinophil numbers are comparable to conventional EoE, but no eosinophils are present in the esophagus, we 
hypothesized that EoE-like disease patients might have a defect in chemoattraction for eosinophils, and determined therefore the 
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expression of chemokines and cytokines crucially involved in eosinophil recruitment. Eotaxin-3 has been identified as the most 
highly induced gene in EoE patients, and the esophageal eotaxin-3 mRNA level correlates strongly with tissue eosinophilia (26). 
Compared to healthy controls, EoE patients have increased epithelial expression of eotaxin-3 (27,28), while EoE-like disease 
patients showed levels between NE and EoE. TSLP and TNF- expression showed similar, but less consistent, results. In 
conclusion, EoE-like disease patients might have a defect in the eosinophil recruitment pathway, leading ultimately to this non-
eosinophilic inflammatory pattern. 
Because the eotaxin-3 gene is IL-13-inducible (26), one could speculate that IL-13 is not over-expressed in the tissue. We 
identified several genes, such as CDH26 and DSG1, known to be dysregulated by IL-13 in esophageal epithelial cells and 
dysregulated in EoE, but only slightly dysregulated in EoE-like disease biopsies. These results, along with the histologic findings, 
suggest that EoE-like disease may present an attenuated Th2 signal. 
Histology revealed no obvious inflammation in EoE-like disease patients, though IHC detected a considerable T cell 
infiltration of the mucosa, similar in intensity to conventional EoE. The rapid clinical response to anti-inflammatory medication 
further supports the key role of this common immunohistologically detectable infiltration in the pathogenesis of this disease. Of 
interest, in contrast to conventional EoE (11), the expression of the CRTH2 receptor on T cells was not significantly increased, 
signifying that patients with an EoE-like disease may have, as with conventional EoE, a chronic T cell inflammation, but unlike 
conventional EoE, no Th2-type inflammatory response. 
 Notably, T cells were located primarily in a peri- and intrapapillary site, suggesting an early stage of inflammation where T 
cells start to migrate into the epithelial layer. The pattern of a dominantly peripapillary T cell infiltration is reminiscent of lymphocytic 
esophagitis (LyE), a recently recognized, histo-pathologically defined disease of another chronic, immune-mediated esophagitis 
(29-32). As in conventional EoE and in EoE-like disease, dysphagia for solids is also the leading symptom of LyE but, unlike EoE, 
affects predominantly older women thereby resembling our EoE-like disease patients (29-32). Today, neither the cytokine 
expression nor the occurrence of chemotactic factors in LyE has been well characterized. However, it is tempting to speculate that 
all three types of chronic, immune-mediated esophagitis – EoE, LyE and EoE-like disease – have a common underlying pathogenic 
mechanism. 
It is well established that, in actively inflamed EoE, mucosal integrity is disturbed (9,12). As such, dilated intercellular spaces, 
referred to as spongiosis, are a common histomorphological feature of active EoE (5). The widening of the gap between epithelial 
cells is considered to be a condition that allows antigens to penetrate into deeper layers of the mucosa, thereby initiating an 
inflammatory response (33,34). The intercellular epithelial connection is largely regulated through tight junctions and desmosomal 
proteins (34). Several studies have concordantly shown that spongiosis and reduced expression of tight junction and desmosomal 
proteins are associated with a reduced mucosal integrity, as assessed by functional tests (33,34). However, it is still an ongoing 
debate as to whether this barrier defect is an EoE-inherent feature, allowing allergens to invade the mucosa and to initiate an 
inflammatory response, or whether it is only a non-specific consequence of the inflammatory condition. This impelled us to search 
histologically for signs of spongiosis and to determine LEKTI, a marker shown to be responsible for epithelial homeostastis (12). In 
contrast to conventional EoE patients, patients with EoE-like disease exhibited no signs of spongiosis in the esophageal epithelium, 
and structural and immunohistological markers of mucosal integrity were not impaired. Expression of LEKTI was not reduced and 
appeared comparable to esophagus-healthy controls. This, together with the finding that, in conventional EoE, successful treatment 
of inflammation restores mucosal integrity, are strong indicators that barrier function defects in EoE are a consequence of active 
eosinophil inflammation and not a disease-inherent feature. 
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In conclusion, the comprehensive evaluation of five members of EoE families, presenting clinically with a syndrome similar to 
EoE, but without esophageal eosinophilia, reveals a substantial T cell and a minor mast cell infiltration clearly detectable by IHC. 
However, the symptomatic response of this EoE-like disease to corticosteroids and the inheritance of conventional EoE in offspring 
strongly suggests a uniform pathogenesis. Conventional EoE, with its predominant eosinophilia, is therefore likely only one 
phenotype of a broader dysphagia spectrum. Our observations have the potential to challenge some established paradigms, for 
instance, the pathogenic role of eosinophils, the currently used diagnostic criteria for EoE, and even the definition of “functional 
dysphagia”, and beg reconsideration in light of this new, distinct, but difficult to diagnose, entity. However, these findings require 
confirmation in well-powered cohorts of patients suffering from sporadic EoE-like disease, including an analysis of the longitudinal 
development of this intriguing disease. Based on our preliminary data, we currently recommend that, when confronted with a 
patient suffering from solid food dysphagia, but not fulfilling the histologic criteria for EoE diagnosis, examinations be extended to 
include the determination of T cell infiltration; eotaxin-3 (allowing a differentiation between EoE-like disease and conventional EoE); 
and MUC4 and CDH26 mRNA expression analyses (allowing a discrimination between EoE-like disease and NE). 
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since clinical presentation. Single data points represent mean values at each time point. 
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Table 1. Demographic, clinical and disease-specific characteristics of patients with EoE-like disease 
      
   
    
 
    
Patient Age Gender 
Age at 
symptom 
onset 
Age at 
diagnosis 
Duration of 
symptoms 
at 
diagnosis 
Symptoms 
History of 
allergies 
BMI 
Laboratory 
findings 
Endoscopic features Histology Treatment response 
  years   years years years Dysphagia 
for solids 
Long-
lasting food 
impaction 
requiring 
endoscopic 
removal 
Spontaneously 
occuring chest 
pain  
AA, ARC, 
OAS * 
kg/m
2
 Peripheral 
blood 
eosinophils 
eos/mm
3
 
(Norm <350 
eos/mm
3
) 
Serum 
IgE 
kU/l       
(Norm 
<100 
kU/l)  
Description EREFS 
Score ** 
HE staining Symptom 
response 
to PPI 
Symptom 
response to 
corticosteroids 
1 60 f 52 59 7 yes no no none 28.1 0 22 few plaques 0/0/0/0/0 
no eosinophils, 
few 
lymphocytes 
 
none 
complete 
resolution 
2 73 f 10 72 62 yes yes no AA, ARC 18.4 200 99 few nodules 0/0/0/0/0 
no eosinophils, 
few 
lymphocytes 
 
none 
complete 
resolution 
3 53 f 10 52 42 yes no no AA 23.2 100 40 few nodules 0/0/0/0/0 
no eosinophils, 
few 
lymphocytes 
 
none 
complete 
resolution 
4 71 f 65 70 5 yes no yes none 24.1 100 15 unremarkable 0/0/0/0/0 
no eosinophils, 
few 
lymphocytes 
 
none 
partial 
resolution 
5 44 m 40 43 3 yes no yes ARC, OAS 23.3 100 102 Subtle rings 0/1/0/0/0 
2 eosinophils in 
1/40 hpf, few 
lymphocytes 
none 
complete 
resolution 
Average, 
ratio 60.2  m/f = 1/4 35.4 59.2 23.8 5/5 1/5 2/5 3/5 23.4           
0/5 4/5 
Range, 
percentage 44 - 73   
10 - 65 43 - 72 3 - 62 100% 20% 40% 60% 
18.4 - 
28.1 
0 - 200 
15 - 
102 
  
    
0% 80% 
SD 10.91    24.82 12.19 26.73         3.43               
 
*  AA=allergic asthma, ARC= allergic rhinoconjunctivits, OAS= oral allergy syndrome 
** EREFS-Score (Edema/Rings/Exudates/Furrows/Strictures):  0=absent 1=mild 2=moderate 3=severe 
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Figure legends 
 
Figure 1. Pedigrees of the four EoE families identified with at least one relative suffering from EoE-like disease. The pedigrees of 
the four EoE families demonstrate that among EoE-like disease patients, 33% of the first generation offspring were affected by 
confirmed conventional EoE and, in total, 40% by EoE and EoE-like disease. 
 
Figure 2. Endoscopic and histologic findings in patients with EoE-like disease. Upper Panel: Representative endoscopic pictures of 
three patients with EoE-like disease, showing an intact, non-inflamed mucosa with discrete abnormalities, such as some fine 
nodules (A and B), as well as subtle rings that disappear spontaneously or after insufflation of air (C). Lower Panel: Representative 
histologic pictures of three patients with EoE-like disease, showing a regularly-structured squamous epithelium with few 
lymphocytes (D and E) in the epithelium and lamina propria, mild basal zone hyperplasia (D), papillary elongation (D and F) and 
minimal sub-epithelial fibrosis (D and F), but no eosinophils. (Elastica van Gieson (D) and HE staining (E and F); original 
magnification x 200). 
 
Figure 3. Inflammatory cell infiltration in EoE-like disease, EoE and healthy controls. Immunohistomorphometric determination of 
epithelial eosinophil, T cell and mast cell numbers in patients with EoE-like disease, conventional EoE and healthy controls (NE), 
demonstrating a lack of eosinophils or extra-cellular EPX granule protein deposits in patients with EoE-like disease (A); a significant 
T cell infiltration comparable with conventional EoE, but mainly with CRTH2 negative T cells (B); as well as a relatively mild 
infiltration with mast cells (C). Right: Representative images. Eosinophils, T cells, and mast cells were identified using the indicated 
lineage-specific antibodies. Nuclei were stained with propidium iodide (PI). In the images of panel B, the epithelial-subepithelial 
junction is highlighted (dashed line). Bars, 10 µm. 
 
Figure 4. Cytokine expression in EoE-like disease, EoE and healthy controls. Immunohistomorphometric determination of 
esophageal cytokine expression in EoE-like disease, conventional EoE, and in healthy controls, revealing a significantly reduced 
expression of the eosinophil chemoattractant, eotaxin-3, as compared with conventional EoE (A), showing similar trends for TSLP 
(B) and for TNF- (C). In contrast to conventional EoE, the expression of the mucosal integrity-associated marker, LEKTI, was not 
reduced (D). Right: Representative images. Eotaxin-3, TSLP, TNF-α, and LEKTI were identified using specific antibodies. Nuclei 
were stained with hematoxylin (panels A and C) and propidium iodide (PI) (panels B and D). Bars, 10 µm. 
 
Figure 5. mRNA expression levels in formalin-fixed paraffin-embedded (FFPE) tissue biopsies from patients with EoE-like disease, 
EoE and healthy controls. Determination of mRNA expression with TaqMan Low Density Arrays (TLDA) for esophageal tissue 
sections from patients with EoE-like disease, conventional EoE and normal esophageal epithelium (NE) demonstrate that the 
eotaxin-3 gene is significantly up-regulated in EoE, but not in EoE-like disease or healthy controls. In contrast, the epithelial-related 
gene, MUC4, is significantly up-regulated in EoE and in EoE-like disease as compared with controls. The EoE genes, CDH26, 
KCNJ2, UPKB and DSG, were found to be remarkably dysregulated in EoE and in EoE-like disease, but less so in the latter. 
Expression levels are shown as normalized to GAPDH (glyceraldehyde-3-phosphate-dehydrogenase) expression. Each biopsy is 
presented as an individual point and genes were analyzed only if the expression level was detectable in at least 4/13 biopsies. 
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Eotaxin-3 mRNA levels in biopsies of patients with EoE-like disease and healthy controls were undetectable. Therefore, the lower 
detection limit of the assay was added in each of these cases (upper left panel).  
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